^
Association details:
| Biomarker: | TACC3 expression |
|---|---|
| Cancer: | Rectal Cancer |
| Drug: | capecitabine (Thymidylate synthase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Pretreatment TACC3 expression in locally advanced rectal cancer decreases the response to neoadjuvant chemoradiotherapy
Excerpt:
...152 rectal cancer patients...received chemoradiotherapy and surgical resection. The neoadjuvant chemotherapy regimens consisted of capecitabine, CapOX (capecitabine and oxaliplatin), FOLFOX, and 5-fluorouracil (5-FU). TACC3 expression significantly decreased sensitivity to chemoradiotherapy [risk ratio (RR) = 2.236, 95% confidence interval (CI): 1.447-3.456; P = 0.001] and thus the pathological complete response rate (P = 0.001).
DOI:
10.18632/aging.101585
